Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The British Journal of Dermatology|August 14, 2019
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)A Wollenberg, L A Beck, A Blauvelt, et al.
The British Journal of Dermatology|February 8, 2019
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitisG Yosipovitch, M Reaney, V Mastey, et al.
The British Journal of Dermatology|February 22, 2019
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trialsJ I Silverberg, E L Simpson, M Ardeleanu, et al.
The British Journal of Dermatology|October 10, 2019
Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extensionM J Cork, D Thaçi, L F Eichenfield, et al.
The British Journal of Dermatology|March 10, 2019
Conjunctivitis in dupilumab clinical trialsB Akinlade, E Guttman-Yassky, M de Bruin-Weller, et al.
The British Journal of Dermatology|July 2, 2014
Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)J R Chalmers, J Schmitt, C Apfelbacher, et al.
The British Journal of Dermatology|April 20, 2018
Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)J R Chalmers, K S Thomas, C Apfelbacher, et al.
The British Journal of Dermatology|July 21, 2016
Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)J R Chalmers, E Simpson, C J Apfelbacher, et al.
Pageof 2